Section Arrow
GLPG.NASDAQ
- Galapagos NV
Quotes are at least 15-min delayed:2024/10/31 20:44 EDT
Last
 26.41
-2.18 (-7.63%)
Day High 
27.45 
Prev. Close
28.59 
1-M High
31.225 
Volume 
569.01K 
Bid
26.38
Ask
27.12
Day Low
26.35 
Open
26.94 
1-M Low
28.1 
Market Cap 
1.88B 
Currency USD 
P/E 54.86 
%Yield -- 
10-SMA 29.65 
20-SMA 29.53 
50-SMA 29.11 
52-W High 42.455 
52-W Low 24.16 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
4.29/-1.84
Enterprise Value
1.89B
Balance Sheet
Book Value Per Share
49.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
239.72M
Operating Revenue Per Share
8.84
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 20:44 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.